Gabriella Gentile, Verona IT
Gabriella Gentile, Verona IT
Patent application number | Description | Published |
---|---|---|
20080269195 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine - Compounds of formula (I) or a salt thereof are disclosed: | 10-30-2008 |
20090030062 | AZABICYCLO [3.1.0] HEXYLPHENYL DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS - The present invention relates to novel compounds of formula (IA) or a salt thereof: | 01-29-2009 |
20090175788 | RADIOLABELLED LIGAND FOR THE GLYCINE 1 TRANSPORTER - Compounds of formula (I) and salts and solvates thereof, which are radiolabelled ligands for the glycine 1 transporter, are provided: | 07-09-2009 |
20090221618 | AZABICYCLO (3, 1, 0) HEXAN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS - The present invention relates to novel compounds of formula (I) or a salt thereof: | 09-03-2009 |
20100016287 | COMPOUNDS HAVING AFFINITY FOR DOPAMINE D3 RECEPTOR AND USES THEREOF" - Compounds of formula (I) | 01-21-2010 |
20100069416 | Azabicyclo [3.1.0] Hexyl Derivatives as Modulators of Dopamine D3 Receptors - The present invention relates to certain azabicyclo compounds of formula (I)′: | 03-18-2010 |
20100075982 | Pyridinone Derivative For The Treatment of Premature Ejaculation - The invention provides 3-(methyloxy)-1-{4-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]butyl}-2(1H)-pyridinone of formula (I), | 03-25-2010 |
20100152195 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors - The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: | 06-17-2010 |
20100160336 | Azabicyclo (3.1.0) Hexane Derivatives Useful As Modulators Of Dopamine D3 Receptors - The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt thereof: | 06-24-2010 |
20110172255 | Condensed N-Heterocyclic Compounds and their Use as CRF Receptor Antagonists - The present invention provides compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions mediated by corticotropin-releasing factor (CRF). | 07-14-2011 |